Novel haplotype tagging single nucleotide polymorphisms and use of same to predict childhood lymphoblastic leukemia
AssigneeMedical Diagnostic Laboratories, LLC
InventorsCharronne Florence Davis, Mehmet Tevfik Dorak
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel haplotype tagging single nucleotide polymorphisms (SNPs) in specific regions outside the HFE gene that serve as a reliable biomarker for a decreased risk for childhood lymphoblastic leukemia (ALL) in a child. There is provided herein methods and reagents for assessing the haplotype tagging SNPs selected from the group consisting of rs807212, rs198853, rs9467664, rs2213284, rs2230655 and rs12346. The method useful in applying these SNPs in predicting a decreased risk of childhood lymphoblastic leukemia (ALL) is also disclosed.
Claims11
A method for predicting childhood acute lymphoblastic leukemia (ALL) in a child, comprising the steps of:
- (a) providing a biological sample;
- (b) isolating nucleic acid from said sample;
- and
- (c) assessing the presence of a haplotype tagging SNP selected from the group consisting of rs807212, rs198853, rs9467664, rs2213284, rs2230655 and rs12346, wherein the presence of said haplotype tagging SNP is indicative of a reduced risk of childhood acute lymphoblastic leukemia in said child.
A method of predicting childhood acute lymphoblastic leukemia (ALL) in a child, comprising the steps of:
- (a) providing a biological sample;
- (b) isolating genomic DNA from said sample;
- and
- (c) assessing the presence of a haplotype tagging SNP rs807212 by genotyping using a TaqMan allelic discrimination assay,
- wherein the presence of said haplotype tagging SNP is indicative of a protective marker for childhood acute lymphoblastic leukemia (ALL) in said child.
Dependencies are inferred from the claim text.